China is the second largest pharmaceutical market in the world, growing to $205bn by 2026. With an increasing focus on innovation and early access, many US biopharmas have found that an anchor in China supports accelerated clinical development and creates incremental value via either through equity ...
Orrick is hosting the 12th Annual Global Dive/In on October 26, 2020. This year, our keynote Dive/In speaker is Professor Ibram X. Kendi, Director of the Center for Anti-Racist Research at Boston University and the author of New York Times Bestseller How to Be An Anti-Racist.
This session will introduce the development of patent infringement litigations involving standard essential patents (SEPs) in China, using some important and recent cases as examples. Yufeng (Ethan) Ma, partner in Orrick's Shanghai Office, will be presenting live from Tokyo.
With the antiquated common law doctrines of maintenance and champerty on their way out in most common law jurisdictions, and a generally permissive landscape available in civil law countries, third party funding is receiving much attention in the Asian region. Join the regional representative of ...
香港を仲裁地とする国際仲裁 - 執行、知的財産、雇用、第三者訴訟融資などに関する実務
How to Proceed with Hong Kong and International Arbitration - Practical Aspects Including Enforcement, Intellectual Property, Employment and Third Party Funding
Orrick’s Tokyo Office Litigation Group is hosting a series of monthly “Orrick Library” ...
Please read before sending e-mail.
Please do not include any confidential, secret or otherwise sensitive information concerning any potential or actual legal matter in this e-mail message. Unsolicited e-mails do not create an attorney-client relationship and confidential or secret information included in such e-mails cannot be protected from disclosure. Orrick does not have a duty or a legal obligation to keep confidential any information that you provide to us. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.
By clicking "OK" below, you understand and agree that Orrick will have no duty to keep confidential any information you provide.